1. Home
  2. AVXL vs MEG Comparison

AVXL vs MEG Comparison

Compare AVXL & MEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • MEG
  • Stock Information
  • Founded
  • AVXL 2004
  • MEG 2012
  • Country
  • AVXL United States
  • MEG United States
  • Employees
  • AVXL N/A
  • MEG N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • MEG Professional Services
  • Sector
  • AVXL Health Care
  • MEG Consumer Discretionary
  • Exchange
  • AVXL Nasdaq
  • MEG Nasdaq
  • Market Cap
  • AVXL 956.7M
  • MEG 985.6M
  • IPO Year
  • AVXL N/A
  • MEG 2020
  • Fundamental
  • Price
  • AVXL $8.63
  • MEG $28.96
  • Analyst Decision
  • AVXL Strong Buy
  • MEG Buy
  • Analyst Count
  • AVXL 3
  • MEG 7
  • Target Price
  • AVXL $44.00
  • MEG $32.57
  • AVG Volume (30 Days)
  • AVXL 1.4M
  • MEG 439.2K
  • Earning Date
  • AVXL 08-12-2025
  • MEG 11-04-2025
  • Dividend Yield
  • AVXL N/A
  • MEG N/A
  • EPS Growth
  • AVXL N/A
  • MEG N/A
  • EPS
  • AVXL N/A
  • MEG N/A
  • Revenue
  • AVXL N/A
  • MEG $780,122,000.00
  • Revenue This Year
  • AVXL N/A
  • MEG $18.02
  • Revenue Next Year
  • AVXL N/A
  • MEG $3.50
  • P/E Ratio
  • AVXL N/A
  • MEG N/A
  • Revenue Growth
  • AVXL N/A
  • MEG 17.79
  • 52 Week Low
  • AVXL $5.22
  • MEG $10.51
  • 52 Week High
  • AVXL $14.44
  • MEG $32.00
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 41.62
  • MEG 54.43
  • Support Level
  • AVXL $8.41
  • MEG $26.75
  • Resistance Level
  • AVXL $9.50
  • MEG $28.12
  • Average True Range (ATR)
  • AVXL 0.48
  • MEG 1.26
  • MACD
  • AVXL -0.05
  • MEG -0.03
  • Stochastic Oscillator
  • AVXL 27.98
  • MEG 53.13

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

About MEG Montrose Environmental Group Inc.

Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.

Share on Social Networks: